JW (Cayman) Therapeutics Co. Ltd announced the grant of 387,740 share options and 77,548 restricted share units to two employees under its Post-IPO Incentivization and Restricted Share Unit Schemes.

JW Therapeutics's latest twelve months p/e ratio is -0.8x JW Therapeutics's p/e ratio increased in 2021 (-4.4x, -34.5%), 2022 (-1.8x, -58.4%), and 2023 (-1.1x, -41.9%). We've identified the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day JWCTF 0.37% DJIA 0.86% Russell 2K 0.24% Health Care/Life Sciences 0.43% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

JW Therapeutics's latest twelve months return on assets is -27.1% JW Therapeutics's return on assets decreased in 2022 (-28.6%, +40.6%) and 2023 (-31.1%, +8.6%) and increased in 2021 (-20.4%, -72.8%).

Check a company’s competitiveness in the job market with alternative data that tracks hiring, job openings, and more.

Click the link below to download a spreadsheet with an example Revenue calculation for Jw Cayman Therapeutics Co Ltd below: The chart above depicts the distribution of Revenue for companies operating ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.